Amgen launches osteoporosis drug at $21,900 per treatment course

Amgen launched Evenity romosozumab-aqqg in the U.S. at $1,825 per month to treat osteoporosis in postmenopausal

Read the full 164 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE